<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04422990</url>
  </required_header>
  <id_info>
    <org_study_id>CLY935-C012</org_study_id>
    <nct_id>NCT04422990</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of a Silicone Hydrogel Daily Wear Monthly Replacement Contact Lens</brief_title>
  <official_title>Clinical Evaluation of a Silicone Hydrogel Daily Wear Monthly Replacement Contact Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the safety and performance of an&#xD;
      investigational soft contact lens compared to a commercially available soft contact lens when&#xD;
      worn in a daily wear modality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be expected to attend 4 office visits: Screening/Baseline/Dispense, Week 1&#xD;
      Follow-up, Month 1 Follow-up, and Month 3 Follow-up/Exit. The total expected duration of&#xD;
      participation for each subject is approximately 3-4 months in this daily wear clinical study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">May 18, 2021</completion_date>
  <primary_completion_date type="Actual">February 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean contact lens corrected distance visual acuity (CLCDVA) at Week 1 Follow-up</measure>
    <time_frame>Week 1</time_frame>
    <description>Visual acuity will be assessed using reading charts while wearing the study lenses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with CLCDVA of 20/20 or better, measured monocularly, in both right eye (OD) and left eye (OS) at Week 1 Follow-up</measure>
    <time_frame>Week 1</time_frame>
    <description>Visual acuity will be assessed using reading charts while wearing the study lenses.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Refractive Errors</condition>
  <arm_group>
    <arm_group_label>LID018869</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lehfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses will be worn for a total of 3 months, with monthly planned replacement over the course of the study duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biofinity</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses will be worn for a total of 3 months, with monthly planned replacement over the course of the study duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lehfilcon A contact lenses</intervention_name>
    <description>Investigational silicone hydrogel contact lenses</description>
    <arm_group_label>LID018869</arm_group_label>
    <other_name>LID018869</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Comfilcon A contact lenses</intervention_name>
    <description>Commercially available silicone hydrogel contact lenses</description>
    <arm_group_label>Biofinity</arm_group_label>
    <other_name>CooperVision® BIOFINITY®</other_name>
    <other_name>Biofinity</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Successful wear of spherical daily wear frequent replacement soft contact lenses for&#xD;
             distance correction in both eyes during the past 3 months for a minimum of 5 days per&#xD;
             week and 8 hours per day;&#xD;
&#xD;
          -  Manifest cylinder equal to or less than 0.75 diopter (D) in each eye;&#xD;
&#xD;
          -  Best spectacle corrected visual acuity (using manifest refraction) of 20/20 or better&#xD;
             in each eye;&#xD;
&#xD;
          -  Other protocol-defined inclusion criteria may apply.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Wearing habitual contact lenses in an extended wear modality (routinely sleeping in&#xD;
             lenses for at least 1 night per week) over the last 3 months prior to enrollment;&#xD;
&#xD;
          -  Habitually wearing Biofinity lenses;&#xD;
&#xD;
          -  Monovision or multifocal contact lens wearers;&#xD;
&#xD;
          -  Other protocol-defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Clinical Trial Lead, CDMA Vision Care</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Novato</city>
        <state>California</state>
        <zip>94945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Downers Grove</city>
        <state>Illinois</state>
        <zip>60515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Boiling Springs</city>
        <state>South Carolina</state>
        <zip>29316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vision correction</keyword>
  <keyword>contact lens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

